Therapeutic PD-L1-antibody from the original Tecentriq® commercial drug targeting the PD-L1-antigen, also referred to as Tecentriq® or atezolizumab antibody. Research-relevant quantities are available as licence-free consumable in an aliquoted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments, biosimilar developers can order different batches at the same time.
What our clients say
”Evidentic can supply different batches of reference products for precilinical research.The quick access to the on-stock batches allows for adhoc ordering, keeps costs down and makes a headstart possible!”
“Evidentic is a new source of cost-efficient therapeutic mAbs for our immonassays. And easy to order!”
“We develop innovative and biosimilar mAbs for a global market. Evidentic’s aRMPs are a great source of cost-efficient reference products for our research and development program.”
“Evidentic gives rapid access to originator biologics and different batches. For biosimilar developers and regulators, it will shorten the time to gauge the analytical acceptance range for multiple CQAs of biotherapeutics.”
Atezolizumab / Tecentriq
|API type||Atezolizumab is an Fc-engineered, humanised IgG1 anti-programmed death-ligand 1 (PD-L1)
monoclonal antibody produced in Chinese hamster ovary cells by recombinant DNA technology
|Pharmacotherapeutic group||Antineoplastic agents, monoclonal antibodies
|Target of antibody||PD-L1; Synonyms: CD274, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, A530045L16Rik, B7h1, Pdcd1l1,
Pdcd1lg1, Pdl1, RGD1566211
|General function||Tecentriq works by attaching to a specific protein in your body called programmed death-ligand 1
(PD-L1). This protein suppresses the body’s immune (defense) system, thereby protecting cancer cells
from being attacked by the immune cells. By attaching to the protein, Tecentriq helps your immune
system to fight your cancer.
(Source EMA , package leaflet)
|Short description||Tecentriq is an anti-cancer medicine that contains the active substance atezolizumab.
(Mechanism of action; Source EMA document)
|Programmed death-ligand 1 (PD-L1) may be expressed on tumour cells and/or tumour-infiltrating
immune cells, and can contribute to the inhibition of the antitumour immune response in the tumour
microenvironment. Binding of PD-L1 to the PD-1 and B7.1 receptors found on T-cells and antigen-presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation and cytokine production.
Atezolizumab is an Fc-engineered, humanised immunoglobulin G1 (IgG1) monoclonal antibody that
directly binds to PD-L1 and provides a dual blockade of the PD-1 and B7.1 receptors, releasing
PD-L1/PD-1 mediated inhibition of the immune response, including reactivating the antitumour
immune response without inducing antibody-dependent cellular cytotoxicity. Atezolizumab spares the PD-L2/PD-1 interaction allowing PD-L2/PD-1 mediated inhibitory signals to persist.
|Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)|
|Original license holder|
|Marketing authorisation numbers||EU/1/17/1220/001
|Marketing authorisation holder||Roche Registration GmbH
(Date of first authorisation: 21 September 2017)
|Name of the manufacturer of the biological active substance||F. Hoffmann-La Roche AG
|Name and address of the manufacturer(s) responsible for batch release||Roche Pharma AG
|Max shelf life||36 months
|Storage conditions||2°C – 8°C
|List of excipients||L-histidine
Glacial acetic acid
Water for injections